About Acceleron Pharma
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company's pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: XLRN
- Previous Close: $26.80
- 50 Day Moving Average: $25.19
- 200 Day Moving Average: $30.51
- 52-Week Range: $22.67 - $41.69
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -14.41
- P/E Growth: 0.00
- Market Cap: $1.01B
- Outstanding Shares: 37,746,000
- Beta: 1.73
- Net Margins: -229.77%
- Return on Equity: -30.75%
- Return on Assets: -26.64%
Companies Related to Acceleron Pharma:
- Current Ratio: 8.96%
- Quick Ratio: 8.96%
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
Where is Acceleron Pharma's stock going? Where will Acceleron Pharma's stock price be in 2017?
11 brokerages have issued 12-month price objectives for Acceleron Pharma's shares. Their predictions range from $39.00 to $63.00. On average, they anticipate Acceleron Pharma's share price to reach $46.80 in the next twelve months.
When will Acceleron Pharma announce their earnings?
Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Acceleron Pharma stock?
Here are some recent quotes from research analysts about Acceleron Pharma stock:
According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (2/10/2017)
Credit Suisse Group analysts commented, "We view Mr Dable’s prior role as President of US Pharmaceuticals Bayer and experience in commercial product launches as a strong strategic fit for XLRN’s future commercialization. Further, Mr Dable brings significant collaboration experience from Bayer deals with Genzyme and Regeneron, where he spearheaded ophthalmology business planning and execution. Our conversation with mgmt. indicates Dr. Knopf will stay involved with XLRN in a scientific capacity, after co-founding the company 13 years ago. Mgmt change prepares XLRN for luspatercept co-commercialization: With ph3 trials in MDS and beta-thalassemia ongoing, we see Mr. Dable bringing significant commercial experience to XLRN. We conservatively model luspatercept sales in ESA-resistant and ring sideroblast-positive (RS+) MDS patients (ph3 MEDALIST population) and transfusion dependent beta- thalassemia patients (ph3 BELIEVE population). We model PoS-unadjusted peak year sales ests. of $908M globally in MDS and $1.1B in beta- thalassemia." (9/28/2016)
FBR & Co analysts commented, "Acceleron Pharma announced preliminary updated positive data from the ongoing Phase II trials with luspatercept in myelodysplastic syndromes (MDS) and beta- thalassemia that are being presented at the 21st Congress of the EHA. The main takeaway from the beta-thalassemia data, in our opinion, is that 67% (20/30) and 83% (20/24) of transfusion-dependent (TD) patients achieved a ≥33% reduction of transfusion burden from 12 weeks pre-treatment to 12 weeks on treatment in the base and extension study, respectively. In the ongoing extension study, 50% (11/22) of patients with lower-risk MDS who were eligible for transfusion independence (TI) achieved red blood cell transfusion independence (RBC-TI) ≥ 8 weeks (range nine to more than 80 weeks)." (6/13/2016)
Who owns Acceleron Pharma stock?
Acceleron Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (13.88%), Novo A S (3.29%), State Street Corp (2.50%), Perceptive Advisors LLC (1.64%), Franklin Resources Inc. (1.28%) and Eventide Asset Management LLC (1.14%). Company insiders that own Acceleron Pharma stock include Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire.
Who sold Acceleron Pharma stock? Who is selling Acceleron Pharma stock?
Acceleron Pharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Century Capital Management LLC, Franklin Resources Inc. and AQR Capital Management LLC. Company insiders that have sold Acceleron Pharma stock in the last year include Jean George, John D Quisel, John L Knopf, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire.
Who bought Acceleron Pharma stock? Who is buying Acceleron Pharma stock?
Acceleron Pharma's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Loomis Sayles & Co. L P, Novo A S, Harbourvest Partners LLC, Guggenheim Capital LLC, State Street Corp, Alden Global Capital LLC and Aberdeen Asset Management PLC UK. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski.
How do I buy Acceleron Pharma stock?
Shares of Acceleron Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Acceleron Pharma stock cost?
One share of Acceleron Pharma stock can currently be purchased for approximately $26.80.